After the efficacy of taxane was shown in advanced breast cancer, the BIG 02-98 trincorporatedatedocetaxelel into the adjuvant setting.
The first evidence of the clinical efficacy of Vorinostat in AML has been shown in patients with advanced hematological disease, where the vast majority was represented by AML.
High levels of total and Mtb-specific serum antibodies have previously been shown in patients with advanced tuberculosis disease [ 27], including cavitary forms of pulmonary tuberculosis [ 28, 29].
Such a relationship has recently been shown in patients with advanced colorectal cancer receiving first-line chemotherapy, though the ability to predict survival for a given tumour response was not as precise as expected (Buyse et al, 2000b).
In the clinical setting, it has been shown in a series of advanced head and neck cancers that the polymorphism in wild-type p53 influences the clinical outcome of the treatment, with significantly shorter survival in homozygous patients with the P variant allele (Bergamaschi et al, 2003).
It has been shown, in elderly patients affected by advanced non-small-cell lung cancer, that the baseline scores are worse for the patients who are going to fill in fewer questionnaires, as compared to the patients who fill in all the planned QOL assessments [ 16].
Furthermore, hyperactivation of AKT signalling has been shown in prostate cells as well as in advanced PCa tissues (Kreisberg et al, 2004).
Ktrans is generally high in tumours, as is kep, and a significant reduction of up to a third has been shown in both parameters in patients with locally advanced breast cancer responding early in their course of neoadjuvant chemotherapy [ 12].
Notably, it was shown in patients with advanced non-small cell lung cancer that the survival time of amphiregulin-negative patients treated with gefitinib was significantly longer than that of amphiregulin-positive patients.
A similar result is shown in patients with advanced gastric cancer (Masuzawa et al, 2012).
